UTRx is pleased to announce that we have filed 5 new patent application mid February 2025 with the USPTO and 1 PCT filed early February 2025.
UTRx is pleased to announce that we have filed 5 new patent application mid February 2025 with the USPTO and 1 PCT filed early February 2025.
The new IPs cover our
- c-MYC drug in pan triple negative breast cancer
- Pan c-MYC pancreatic cancer
- Pan c-MYC ovarian cancer
- Novel Mechanism of ribosome fate switching
- Novel Pan MYCN cancer drug for childhood and adult cancer
The PCT covers our novel TEAD1 and YAP1 drug targeting hippo pathway driven cancer
